Autopsy report · NCT05319093

Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients

“Funding ended prematurely”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 4 months before it stopped.
• 26 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Brigham and Women's Hospital

Sponsor type

University, hospital or other

Conditions

Fatigue; Multiple Sclerosis

Interventions

Ozanimod

Participants

26

Sites

1

Countries

United States

Trials that died the same way

• Gene Expression in Tumor Tissue From Women Undergoing Surgery for Breast Cancer or Core Biopsy of the Breast
  “Funding ended” (92% match in meaning)
• Role of FCI in the Detection of Proctosigmoiditis Caused by IBD
  “Funding period ended” (88% match in meaning)
• Auricular Point Acupressure: Examining the Scientific Underpinnings of Pain Relief
  “Funding duration ended.” (87% match in meaning)
• A Study of APR-246 in Oesophageal Cancer
  “Funding ceased” (86% match in meaning)
• Effectiveness of the Rapid Intravascular Start (RIVS) System Versus Conventional Catheter
  “Funding Stopped” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.